R\u00e9sum\u00e9 :
\nLes fabricants de m\u00e9dicaments poursuivent \u00e0 nouveau la Food and Drug Administration (FDA) concernant des m\u00e9dicaments contre l’ob\u00e9sit\u00e9 et le diab\u00e8te. Ils affirment que la d\u00e9cision de l’agence de retirer le semaglutide de Novo Nordisk de sa liste de p\u00e9nurie “privera les patients d’un traitement vital”. La d\u00e9claration initiale de p\u00e9nurie autorisait ces fabricants \u00e0 proposer des versions alternatives du semaglutide, vendu par Novo sous les noms Wegovy pour la perte de poids et Ozempic pour le diab\u00e8te. Cette nouvelle action en justice suit une pr\u00e9c\u00e9dente contre la FDA concernant le retrait du tirzeptatide d\u2019Eli Lilly de la liste, un dossier toujours en cours. <\/p>\n
L’entreprise de sant\u00e9 en ligne Hims & Hers, un important vendeur de semaglutide compos\u00e9, pr\u00e9voit d’informer bient\u00f4t ses clients de chercher des “options alternatives pour le dosage commercial”, a d\u00e9clar\u00e9 son PDG, Andrew Dudum. Les actions de l’entreprise ont chut\u00e9 d’un tiers depuis l’annonce de la FDA.<\/p>\n
Contexte :
\nLa d\u00e9claration de la FDA impose aux fabricants de cesser de proposer leurs versions de semaglutide d’ici le 22 avril ou le 22 mai, selon leur type d’autorisation l\u00e9gale. Dans leur plainte, l’Outsourcing Facilities Association et North American Custom Laboratories affirment que la d\u00e9cision est “arbitraire, capricieuse et contraire \u00e0 la loi”, car la FDA n’a pas pr\u00e9venu \u00e0 l’avance ni permis de commentaires publics.<\/p>\n
Les fabricants soutiennent qu’une p\u00e9nurie existe toujours car la FDA reconna\u00eet encore des “perturbations d’approvisionnement localis\u00e9es et intermittentes”, et Novo a mentionn\u00e9 que les “contraintes d’approvisionnement” peuvent persister. La plainte affirme que la FDA a agi pour “favoriser des int\u00e9r\u00eats particuliers, augmenter les prix des m\u00e9dicaments, et priver le public d\u2019un acc\u00e8s \u00e0 un m\u00e9dicament n\u00e9cessaire”.<\/p>\n
Hims, qui a gagn\u00e9 225 millions de dollars de revenus gr\u00e2ce au semaglutide compos\u00e9 et \u00e0 d’autres m\u00e9dicaments de la classe GLP-1 en 2024, pr\u00e9voit de se conformer \u00e0 la d\u00e9cision de la FDA. L’entreprise pr\u00e9voit un chiffre d’affaires de 725 millions de dollars avec les m\u00e9dicaments pour la perte de poids, m\u00eame sans contribution croissante du semaglutide, et des b\u00e9n\u00e9fices entre 270 et 320 millions de dollars.<\/p>\n
Hims pr\u00e9voit d’atteindre cet objectif de revenus gr\u00e2ce \u00e0 la “personnalisation” des doses de semaglutide, une approche l\u00e9gale pour att\u00e9nuer les effets secondaires du m\u00e9dicament.<\/p>\n
Pendant que les fabricants poursuivent leur lutte, Novo et Lilly r\u00e9agissent avec des actions l\u00e9gales et des lettres publiques sur les risques des m\u00e9dicaments compos\u00e9s. Par ailleurs, Lilly teste une nouvelle strat\u00e9gie de vente avec un programme d’auto-paiement et a annonc\u00e9 baisser les prix de certaines doses de Zepbound.<\/p>\n","protected":false},"excerpt":{"rendered":"
Le fournisseur de t\u00e9l\u00e9sant\u00e9 Hims & Hers a annonc\u00e9 qu’il informera les consommateurs qu’ils doivent rechercher “des options alternatives pour le dosage commercial”. Cependant, l’entreprise pr\u00e9voit toujours une augmentation de ses revenus et de ses b\u00e9n\u00e9fices en 2025.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[684],"tags":[],"class_list":["post-69602","post","type-post","status-publish","format-standard","hentry","category-nouvelles-pharmaceutiques"],"_links":{"self":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/comments?post=69602"}],"version-history":[{"count":1,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69602\/revisions"}],"predecessor-version":[{"id":69642,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69602\/revisions\/69642"}],"wp:attachment":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/media?parent=69602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/categories?post=69602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/tags?post=69602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}